Anika Therapeutics
ANIK
164 hedge funds and large institutions have $381M invested in Anika Therapeutics in 2020 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 57 increasing their positions, 58 reducing their positions, and 42 closing their positions.
2% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 58
2.83% less ownership
Funds ownership: 95.72% → 92.89% (-2.8%)
14% less funds holding
Funds holding: 191 → 164 (-27)
46% less capital invested
Capital invested by funds: $708M → $381M (-$327M)
55% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 42
62% less call options, than puts
Call options by funds: $1.83M | Put options by funds: $4.83M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$6.8M |
| 2 |
Renaissance Technologies
New York
|
+$6.58M |
| 3 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
+$4.31M |
| 4 |
Los Angeles Capital Management
Los Angeles,
California
|
+$3.63M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$3.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$5.22M |
| 2 |
Morgan Stanley
New York
|
-$4.36M |
| 3 |
MCM
Matarin Capital Management
New York
|
-$4M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.94M |
| 5 |
Goldman Sachs
New York
|
-$3.49M |
ANIK Hedge Fund Activity: Q1 2020 in Review
164 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q1 2020, worth a combined $381M — down 46% from $708M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of ANIK and 19 opened new positions — a net loss of 23 holders — while 58 trimmed existing stakes and 57 added.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $6.8M. The largest seller was Arrowstreet Capital, cutting an estimated $5.22M.
- 164 institutional investors held Anika Therapeutics (ANIK) as of Q1 2020, down from 191 in Q4 2019.
- Funds reported $381M of Anika Therapeutics stock for Q1 2020, down 46% quarter-over-quarter.
- 19 funds opened new Anika Therapeutics positions in Q1 2020 and 42 closed out, a net change of -23 holders.
- The largest Anika Therapeutics buyer in Q1 2020 was Avidity Partners Management, an estimated $6.8M added.
- The largest Anika Therapeutics seller in Q1 2020 was Arrowstreet Capital, an estimated $5.22M sold.
Based on aggregated 13F filings for Q1 2020.